ATE294794T1 - N-heterocyclylhydrazide als neurotrophe mittel - Google Patents
N-heterocyclylhydrazide als neurotrophe mittelInfo
- Publication number
- ATE294794T1 ATE294794T1 AT02800473T AT02800473T ATE294794T1 AT E294794 T1 ATE294794 T1 AT E294794T1 AT 02800473 T AT02800473 T AT 02800473T AT 02800473 T AT02800473 T AT 02800473T AT E294794 T1 ATE294794 T1 AT E294794T1
- Authority
- AT
- Austria
- Prior art keywords
- heterocyclylhydrazides
- disease
- neurotrophic agents
- palsy
- parkinson
- Prior art date
Links
- 230000000508 neurotrophic effect Effects 0.000 title abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000006373 Bell palsy Diseases 0.000 abstract 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 208000036826 VIIth nerve paralysis Diseases 0.000 abstract 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 230000001537 neural effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32701901P | 2001-10-04 | 2001-10-04 | |
| PCT/US2002/031678 WO2003029247A1 (en) | 2001-10-04 | 2002-10-04 | N-heterocyclyl hydrazides as neurotrophic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE294794T1 true ATE294794T1 (de) | 2005-05-15 |
Family
ID=23274781
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02800473T ATE294794T1 (de) | 2001-10-04 | 2002-10-04 | N-heterocyclylhydrazide als neurotrophe mittel |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US7087628B2 (de) |
| EP (1) | EP1448553B1 (de) |
| JP (1) | JP2005506335A (de) |
| AT (1) | ATE294794T1 (de) |
| AU (1) | AU2002334836B2 (de) |
| CA (1) | CA2462419A1 (de) |
| DE (1) | DE60204046T2 (de) |
| ES (1) | ES2242096T3 (de) |
| MX (1) | MXPA04003216A (de) |
| WO (1) | WO2003029247A1 (de) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1918286B1 (de) * | 2006-11-05 | 2011-12-21 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Thiazolhydrazide und deren Verwendung zur Behandlung von neurodegenerativen Krankheiten |
| WO2012027548A1 (en) * | 2010-08-25 | 2012-03-01 | The Feinstein Institute For Medical Research | Compounds and methods for prevention and treatment of alzheimer's and other diseases |
| WO2018107853A2 (en) | 2016-09-26 | 2018-06-21 | Qingdao Primedicine Pharmaceutical Co., Ltd. | N-methyl-d-aspartate receptor allosteric modulators and methods for their use |
| PL233208B1 (pl) * | 2018-09-17 | 2019-09-30 | Politechnika Wroclawska | Iminowe pochodne aldehydów salicylowych i hydrazydu kwasu 4-hydroksybenzoesowego oraz sposób ich wytwarzania |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4665173A (en) * | 1982-03-31 | 1987-05-12 | Klayman Daniel L | 2-acetyl- and 2-propionylpyridine selenosemicarbazones |
| US4694004A (en) * | 1984-07-09 | 1987-09-15 | Fujisawa Pharmaceutical Co., Ltd. | Semicarbazide derivatives, processes for preparation thereof and pharmaceutical composition comprising the same |
| ES2161594B1 (es) * | 1998-12-17 | 2003-04-01 | Servier Lab | Nuevos derivados de la hidrazida, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen. |
| US6323215B1 (en) | 1999-07-09 | 2001-11-27 | Ortho-Mcneil Pharmaceutical, Inc. | Neurotrophic tetrahydroisoquinolines and tetrahydrothienopyridines, and related compositions and methods |
| AU5483500A (en) | 1999-07-09 | 2001-01-30 | Ortho-Mcneil Pharmaceutical, Inc. | Neurotrophic 2-azetidinecarboxylic acid derivatives, and related compositions and methods |
| EP1358178A2 (de) * | 2001-01-30 | 2003-11-05 | Bristol-Myers Squibb Company | Sulfonamidlactam-inhibitoren von faktor xa |
-
2002
- 2002-10-04 EP EP02800473A patent/EP1448553B1/de not_active Expired - Lifetime
- 2002-10-04 MX MXPA04003216A patent/MXPA04003216A/es active IP Right Grant
- 2002-10-04 CA CA002462419A patent/CA2462419A1/en not_active Abandoned
- 2002-10-04 US US10/264,997 patent/US7087628B2/en not_active Expired - Lifetime
- 2002-10-04 WO PCT/US2002/031678 patent/WO2003029247A1/en not_active Ceased
- 2002-10-04 ES ES02800473T patent/ES2242096T3/es not_active Expired - Lifetime
- 2002-10-04 AU AU2002334836A patent/AU2002334836B2/en not_active Expired - Fee Related
- 2002-10-04 DE DE60204046T patent/DE60204046T2/de not_active Expired - Lifetime
- 2002-10-04 JP JP2003532495A patent/JP2005506335A/ja active Pending
- 2002-10-04 AT AT02800473T patent/ATE294794T1/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2462419A1 (en) | 2003-04-10 |
| EP1448553B1 (de) | 2005-05-04 |
| US20030144262A1 (en) | 2003-07-31 |
| DE60204046D1 (de) | 2005-06-09 |
| HK1066223A1 (en) | 2005-03-18 |
| WO2003029247A1 (en) | 2003-04-10 |
| ES2242096T3 (es) | 2005-11-01 |
| JP2005506335A (ja) | 2005-03-03 |
| EP1448553A1 (de) | 2004-08-25 |
| US7087628B2 (en) | 2006-08-08 |
| AU2002334836B2 (en) | 2008-04-17 |
| MXPA04003216A (es) | 2005-01-25 |
| DE60204046T2 (de) | 2006-01-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA05002420A (es) | Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos. | |
| GB0129260D0 (en) | Pharmaceutical compositions and their uses | |
| MY138252A (en) | Azabicyclic-substitud fused-heteroaryl compounds for the treatment of disease | |
| GB0225475D0 (en) | Therapeutic agents | |
| GB0318447D0 (en) | Therapeutic agents | |
| SE0001899D0 (sv) | New compounds | |
| DE602004030222D1 (de) | 2-oxo-1,3,5-perhydrotriazapinderivate, die sich zur behandlung von hyperproliferativen, angiogenen und entzündlichen erkrankungen eignen | |
| GB0223038D0 (en) | Therapeutic compounds | |
| BR0214035A (pt) | Composto | |
| GB0225474D0 (en) | Therapeutic agents | |
| EP1673078A4 (de) | Benzylether- und benzylamino-beta-sekretase-hemmer zur behandlung von alzheimer-krankheit | |
| ATE385419T1 (de) | Dermatologische und kosmetische zusammensetzungen enthaltend ein furfurylderivat | |
| EA200600971A1 (ru) | Применение замещённых 2 - аминотетралинов для профилактического лечения болезни паркинсона | |
| ATE409480T1 (de) | Pyrazoloä3,4-büpyridin-6-one als gsk-3 inhibitoren | |
| ATE371724T1 (de) | Behandlung neurodegenerativer krankheiten | |
| ATE334965T1 (de) | Piperidinverbindungen als muscarinantagonisten | |
| SE0104331D0 (sv) | Novel compounds | |
| EP1736470A3 (de) | Pyrimidin-Derivate als cb2 Cannabinoid-Rezeptor Modulatoren | |
| MY139368A (en) | Novel cyclohexyl sulphones | |
| NO20010940D0 (no) | TAN-1057 derivater | |
| MXPA04001419A (es) | Isoxazolopiridinonas y su uso en el tratamiento de enfermedad de parkinson. | |
| BG104179A (en) | Phanquinon administration for the treatment of the alzheimer's disease | |
| ATE294794T1 (de) | N-heterocyclylhydrazide als neurotrophe mittel | |
| DE602004019500D1 (en) | 4-substituirte-5-cyano-1h-pyrimidin-6-(th)iones als als gsk-3-hemmer | |
| AU4568400A (en) | Sphingomyelinase inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |